ALBERTO PAPI

Full Professor of Respiratory Medicine, Head Respiratory Medicine

University of Ferrara

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Alberto Papi is a Full Professor of Respiratory Medicine and the Head of the Respiratory Medicine department at the University of Ferrara, Italy. His research primarily focuses on chronic obstructive pulmonary disease (COPD) and asthma, with recent articles exploring topics such as multimorbid patient management, small airways dysfunction, and the effectiveness of various treatments including Dupilumab and Mepolizumab. His work contributes significantly to the understanding and treatment of respiratory conditions, particularly in relation to inflammation and quality of life outcomes.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Helen Reddel

Macquarie University

AUSTRALIA

ALBERTO PAPI

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Neutrophilic inflammation in sputum or blood does not define a clinically distinct asthma phenotype in ATLANTIS

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation

Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

A person-centred clinical approach to the multimorbid patient with COPD

Mucus production and chronic obstructive pulmonary disease, a possible treatment target: zooming in on N-acetylcysteine

Validity of the Chronic Airways Assessment Test (CAAT) in asthma, asthma+COPD and COPD in NOVELTY

Detecting small airways dysfunction in asthma: Rationale, findings, and future of ATLANTIS

Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)

Questions in Mild Asthma: An Official American Thoracic Society Research Statement

Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of ICS dose

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma

Symptom Burden, Health Status, and Productivity in Patients with Uncontrolled and Controlled Severe Asthma in NOVELTY

Comparison of the Asthma Control Questionnaire and patient diaries in uncontrolled asthma

Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19

Development of a tool to detect small airways dysfunction in asthma clinical practice

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma

Collaborators (16)

Helen Reddel

Abebaw Yohannes

Richard Beasley

Surya Bhatt

Christine Jenkins

Mona Bafadhel

Marc Humbert

Erik Melén

Leonardo Fabbri

Michael G. Ison

Alessandro Vatrella

Njira Lugogo

Guy Brusselle

Ian Pavord

Tessa Kole

Paul Bird

Make your next move.